Drug developers have been acquiring complimentary programs to reduce execution risk and maintain investor interest.

The former was weighed down by CSL (ASX:CSL) ’s guidance cut. CSL plunged 15% after slashing earnings guidance and shelving ...

Macquarie Bank’s provision of funding for QPM Energy’s Issac Power Station is a sign that east coast plays could have more ...

Wellness has gone to a trillion-dollar lifestyle, and EZZ Life Science is diving straight into America’s booming self-care ...

Quarterly season is almost done, and David Franklyn joins to give his best and worst September gold performers, plus a ...

Investors expecting an upbeat update at CSL's AGM have been left disappointed, with low US vaccination rates prompting an ...

Mount Ridley left the pack in its dust on Tuesday, clocking a 140% gain to take the lead in Australia’s gallium race.

Shareholders footed a $5.7m bill for Atlassian’s climate warrior CEO to fly private, while BHP’s $5.5m Telethon donation ...

Heavy falls in the healthcare and tech sectors are dragging the Aussie bourse lower, despite seven of the 11 sectors moving ...

Backed by South Korean industrial giant POSCO, Black Rock Mining views its Mahenge project as a standout graphite development ...

High gold prices are powering new drilling in WA's Bryah Basin by ASX explorers, out to prove we've been looking through the ...